Tumor cell apoptosis pathway activation

Tumor cell apoptosis pathway activation refers to the induction of programmed cell death (apoptosis) in cancer cells, which is a major mechanism for anticancer therapy[2][3][4]. Apoptosis can occur via two canonical pathways:\n- Extrinsic pathway, initiated by activation of *death receptors* (such as TNFR1, Fas, DR4/DR5) through binding of ligands (TNFα, Fas ligand, TRAIL)[2][3][4][6]. This leads to formation of a death-inducing signaling complex (DISC), recruitment and activation of *caspase-8*, and subsequent execution of cell death[3][6].\n- Intrinsic pathway, initiated by cellular stress or DNA damage, mainly regulated by the *BCL-2 family* of proteins, which control mitochondrial outer membrane permeabilization (MOMP), release of *cytochrome c* and *SMAC*, and activation of *caspase-9* through *apoptosome* formation[4][6].\n\nTherapeutic approaches target these pathways by acting on their components (e.g. death receptors, caspases, BCL-2 proteins, Apaf-1), but the pathway activation itself is not a distinct molecular entity suitable for drug targeting or cataloging as a receptor, enzyme, or transporter[2][4][5][6]. Drugs and biological agents may activate the apoptosis machinery to kill tumor cells selectively, but drug development focuses on specific molecular targets within the pathway[5][6].\n\nIn summary, "Tumor cell apoptosis pathway activation" describes a therapeutic strategy, not a canonical drug target. For structured database purposes, this entry should be corrected to the specific molecule or receptor involved (e.g. "Death receptor 5", "BCL-2", "Caspase-8").

Other names

Apoptosis activation in cancer cellsInduction of tumor cell death